The impact of malaria

 Quick Facts:

 

 

· Malaria kills an African child every 30 seconds  

· 300 million acute cases of malaria occur worldwide annually  

· 1 million deaths are attributed to malaria each year  

· 45 million pregnant women are at risk of contracting malaria this year  

· 9 out of 10 cases of malaria occur in sub-Saharan Africa  

· 90% of deaths due to malaria occur in Africa south of the Sahara, mostly among young children  

· In sub-Saharan Africa, up to 40% of low birth weight is due to maternal malaria with up to 400,000 infant deaths every year as a result  

In 2006 at least 120 million ACT treatment courses will be required globally (WHO forecast)

Malaria is an infection caused by a parasite and carried from person to person by mosquitoes. It is preventable and treatable but kills more than one million people, most of them young children living in Africa, each year.

Geographical impact
Today approximately 40% of the world's population, mostly those living in the world's poorest countries, is susceptible to malaria. Malaria is endemic in nearly 100 countries worldwide and notably so in 28 countries on the African continent.

 Symptoms

The disease is characterized by extreme exhaustion associated with fits of high fever, sweating, shaking chills, and anemia. The malaria parasites destroy red blood cells in the body, causing anaemia. Without adequate treatment, infected red blood cells block vessels to the brain or damage other vital organs, often resulting in death. In some instances people in highly endemic areas who are infected frequently may develop immunity to the disease and become asymptomatic carriers of malaria, contributing to epidemics.

Effective treatment

Older, inexpensive, single drugs such as chloroquine are increasingly resistant to new strains of the disease.  The most effective treatments to date involve combinations of artemisinin-based drugs and other antimalarials to prolong an individual drug’s effectiveness and delay resistance.

The World Health Organisation (WHO) recommends that all countries experiencing resistance to conventional monotherapies, such as chloroquine, amodiaquine or sulfadoxine–pyrimethamine, should use combination therapies, preferably those containing artemisinin derivatives (ACTs: artemisinin-based combination therapies) for falciparum malaria. The increase in demand for ACTs has lead to supply issues which threaten the effective treatment of the disease.

The economic impact of malaria

Malaria affects the health and wealth of nations and individuals alike. In Africa today, malaria is understood to be both a disease of poverty and a cause of poverty. In addition to the human cost, malaria has significant measurable direct and indirect costs, and has recently been shown to be a major constraint to economic development. For developing economies this has meant that the gap in prosperity between countries with malaria and countries without malaria has become wider every single year.

Economists believe that malaria is responsible for a ‘growth penalty’ of up to 1.3% per year in some African countries. When compounded over the years, this penalty leads to substantial differences in GDP between countries with and without malaria and severely restrains the economic growth of the entire region.

 

* Sources

World Health Organization www.who.int

One World Health www.oneworldhealth.org

As Summarized by Centre for Novel Agricultural Products – Artemisia Projects 

http://www.york.ac.uk/org/cnap/artemisiaproject